• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Update on anti-CTLA-4 antibodies in clinical trials.
【24h】

Update on anti-CTLA-4 antibodies in clinical trials.

机译：临床试验中抗CTLA-4抗体的更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events.
机译：目前，打破对肿瘤自身抗原的免疫耐受性是癌症疗法设计中的一个深入研究领域。增强针对肿瘤抗原的免疫系统活化的一种可能方法是通过阻断由活化T细胞上表达的细胞毒性T淋巴细胞抗原4（CTLA-4）介导的抑制性共刺激信号。针对人CTLA-4，ipilimumab（Medarex / Bristol-Myers Squibb）和CP-675,206（Pfizer / Abgenix，现为Amgen）的完全人类单克隆抗体已显示出对转移性黑素瘤，激素难治性前列腺癌和其他恶性肿瘤的活性。他们还发现了异常的与免疫相关的不良事件，表现为肠，皮肤和垂体的自限性炎症反应。本文回顾了I，II和III期研究的临床前发展以及有关所报道的终点和免疫相关不良事件的数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号